Head to Head Analysis: Autonomix Medical (NASDAQ:AMIX) & Atossa Genetics (NASDAQ:ATOS)

Autonomix Medical (NASDAQ:AMIX) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Autonomix Medical and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-213.42%	-172.57%
Atossa Genetics	N/A	-49.42%	-44.76%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Autonomix Medical and Atossa Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1	1	1	0	2.00
Atossa Genetics	2	0	2	1	2.40

Autonomix Medical presently has a consensus price target of $5.00, suggesting a potential upside of 825.93%. Atossa Genetics has a consensus price target of $6.33, suggesting a potential upside of 926.14%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Autonomix Medical.

Earnings & Valuation

This table compares Autonomix Medical and Atossa Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$11.41 million	($4.65)	-0.12
Atossa Genetics	N/A	N/A	-$25.50 million	($0.24)	-2.57

Atossa Genetics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Autonomix Medical has a beta of -2.59, indicating that its stock price is 359% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Institutional and Insider Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by insiders. Comparatively, 9.5% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Atossa Genetics beats Autonomix Medical on 10 of the 12 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.